About Us
The Buchholz Lab
Systems biology and genome engineering are at the forefront of transforming our healthcare system. The Department of Medical Systems Biology at the University Cancer Center of TU Dresden integrates functional genomics, high-throughput biology and genome editing to transform precision medicine. Join us in shaping the future of healthcare science!
Prof. Dr. Frank Buchholz
Frank is passionate about the development and application of functional genomics and genome engineering in biomedical science. He was one of the first scientists to perform genome-scale RNAi screens in human cells, and has pioneered genome surgery as a disruptive new biotechnology. Frank has also been a strong leader in industrial innovation and co-founded several biotechnology companies.
Prof. Dr. Frank Buchholz
Frank is passionate about the development and application of functional genomics and genome engineering in biomedical science. He was one of the first scientists to perform genome-scale RNAi screens in human cells, and has pioneered genome surgery as a disruptive new biotechnology. Frank has also been a strong leader in industrial innovation and co-founded several biotechnology companies.
Research
Find out more about our research
Publications
Follow the work of our researchers
Members
Your contact to our research group members
News
Get to know the news of our research group
News
Precision Genome Writing: Three New Reviews by the Buchholz Lab
6. August 2026
Take a look at three recent reviews that together outline a complete pipeline for next‑generation genome editing: Wang P, Sayed S, Buchholz F. Restoring Cancer Genomes: Functional Mutation Correction…
Innovations in Gene Therapy: An Interview with Dr. Shady Sayed
24. February 2026
Dr. Shady Sayed, a leading translational scientist in Germany’s National Translational Tandem Program for Gene- and Cell-Based Therapies (nTTP-GCT), shares his insights in a featured interview.…
Seamless Therapeutics announces global research collaboration with Lilly to develop programmable recombinase-based therapeutics for hearing loss
28. January 2026
Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development…













